Quarterly ResultMay 13, 2026, 05:21 PM
Aptose Q1 Net Loss $7.6M; Hanmi Acquisition Delayed; EHA Presentation
AI Summary
Aptose Biosciences reported a net loss of $7.6 million for the first quarter of 2026, an increase from $5.5 million in the comparable period of 2025, with research and development expenses rising to $3.6 million. The company announced a delay in the closing of its acquisition by Hanmi Pharmaceutical due to pending Korean regulatory approvals, though completion is still targeted for May. Additionally, data from its TUSCANY clinical trial for tuspetinib in AML has been selected for an oral presentation at the upcoming EHA 2026 Congress, and Aptose returned the luxeptinib license rights to CGI.
Key Highlights
- Q1 2026 net loss increased to $7.6M from $5.5M in Q1 2025.
- Research and development expenses rose to $3.6M from $2.4M year-over-year.
- Cash and restricted cash totaled $4.1M as of March 31, 2026.
- Acquisition by Hanmi Pharmaceutical delayed due to pending Korean regulatory approvals.
- TUSCANY trial data for tuspetinib selected for oral presentation at EHA 2026.
- Aptose returned luxeptinib license rights to CGI.